Encapsulation of native crotoxin in liposomes: a safe approach for the production of antivenom and vaccination against Crotalus durissus terrificus venom.
Crotoxin, the neurotoxic component of Crotalus durissus terrificus (Cdt) venom that displays phospholipase A2 activity, was successfully encapsulated into dehydration-rehydration vesicles (DRV/crotoxin) and reverse-phase evaporation vesicles (REV/crotoxin) made from sphingomyelin and cholesterol. The encapsulation efficiency of native crotoxin was higher in DRV/crotoxin than in REV/crotoxin. DRV/crotoxin was not toxic when i.v. inoculated in mice at a dose of crotoxin as high as 91 times its L.D50 or when s.c. inoculated at 42 times its LD50. On the other hand, crotoxin released from DRV/crotoxin retained its original toxicity. REV/crotoxin was found to be at least 1.9 times more toxic than DRV/crotoxin. The fact that DRV/crotoxin retained crotoxin more efficiently than REV/crotoxin may account for the difference in acute toxicity between the two preparations. DRV/crotoxin, when s.c. inoculated in mice, induced anti-crotoxin antibodies that protected animals against the lethal effect of Cdt venom. Following immunization with three doses of DRV/crotoxin (3 x 20 micrograms of crotoxin/mouse) and challenge with 8 x LD50 of Cdt venom, 75% of mice were protected. The DRV/crotoxin preparation was compared to crotoxin emulsified in Freund's adjuvant (FCA/crotoxin). DRV/crotoxin was found to be less toxic than FCA/crotoxin, and to induce lower levels of anti-crotoxin antibodies but similar levels of protection when inoculated at high doses (20 or 70 micrograms crotoxin/mouse). When DRV/crotoxin was adsorbed to alum at the time of immunization, it induced antibody and protection levels comparable to those produced by FCA/crotoxin.
Freitas
T V
TV
Centro de Pesquisa e Desenvolvimento, Fundaçào Ezequiel Dias (FUNED), Belo Horizonte, Minas Gerais, Brazil.
Frézard
F
F
D000818:Animals; D000997:Antivenins / Q000096:biosynthesis* / Q000378:metabolism / Q000633:toxicity; D003439:Crotoxin / Q000276:immunology* / Q000378:metabolism / Q000633:toxicity; D004337:Drug Carriers; D004355:Drug Stability; D005260:Female; D005620:Freund's Adjuvant; D007115:Immunization Schedule; D008081:Liposomes; D051379:Mice; D008815:Mice, Inbred Strains; D016019:Survival Analysis; D014614:Vaccines, Synthetic / Q000276:immunology* / Q000378:metabolism / Q000633:toxicity
D000997:Antivenins; D004337:Drug Carriers; D008081:Liposomes; D014614:Vaccines, Synthetic; D003439:Crotoxin; D005620:Freund's Adjuvant